621 Results for "

MAPK pathways

" in MedChemExpress (MCE) Product Catalog:

Products (621)

Sort by :

Categories

By Targets

Products

323

Sorafenib

323 Publications Verification

Cat. No.: HY-10201

CAS No.: 284461-73-0

Purity: 99.92%

Synonyms: Bay 43-9006

Target:

Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family Ephrin Receptor PDGFR

Research Areas:

Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Sorafenib (Bay 43-9006) is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib inhibits tumor growth and metastasis in mouse and rat models. Sorafenib can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

323

Sorafenib tosylate

323 Publications Verification

Cat. No.: HY-10201A

CAS No.: 475207-59-1

Purity: 99.75%

Synonyms: Bay 43-9006 tosylate

Target:

Raf VEGFR FLT3 Autophagy Apoptosis STAT Akt MMP Cadherin p38 MAPK ERK MEK PI3K PARP Bcl-2 Family

Research Areas:

Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer

Sorafenib (Bay 43-9006) tosylate is a potent oral active multikinase inhibitor. Sorafenib blocks autophosphorylation and activity of receptor tyrosine kinases (VEGFR-2, VEGFR-3) and RAF family kinases, thereby suppressing the RAF/MEK/ERK and PI3K/Akt pathways, inhibiting STAT3 phosphorylation, and selectively inhibiting the MAPK pathway in cancer cells. Sorafenib tosylate induces cell cycle arrest, autophagy, apoptosis, and PARP cleavage, reduces Bcl-2, Bcl-XL, cyclin D1 levels, and activates Bak and Bax. Sorafenib tosylate inhibits tumor growth and metastasis in mouse and rat models. Sorafenib tosylate can be used for cancer research, such as colon, breast, non-small-cell lung cancer (NSCLC), ovarian, pancreatic, melanoma, colorectal and hepatocellular carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

138

Alpelisib

138 Cited Publications

Cat. No.: HY-15244

CAS No.: 1217486-61-7

Purity: 99.88%

Synonyms: BYL-719

Target:

PI3K Apoptosis

Research Areas:

Infection Neurological Disease Metabolic Disease Cancer

Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

138

Alpelisib hydrochloride

138 Cited Publications

Cat. No.: HY-15244A

CAS No.: 1584128-91-5

Synonyms: BYL-719 hydrochloride

Target:

PI3K Apoptosis

Research Areas:

Infection Neurological Disease Metabolic Disease Cancer

Alpelisib (BYL-719) hydrochloride is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib hydrochloride also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib hydrochloride not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib hydrochloride can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Dimethyl fumarate

70 Cited Publications

Cat. No.: HY-17363

CAS No.: 624-49-7

Category:

Infection Natural Products Neurological Disease Endogenous metabolite Disease Research Fields Inflammation/Immunology

Target:

Keap1-Nrf2 Reactive Oxygen Species (ROS) HIV Autophagy Endogenous Metabolite

Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Daporinad

68 Cited Publications

Cat. No.: HY-50876

CAS No.: 658084-64-1

Synonyms: FK866; APO866

Target:

NAMPT Autophagy Apoptosis mTOR p38 MAPK ERK

Research Areas:

Cancer

Daporinad (FK866) is a non-competitive inhibitor of nicotinamide phosphoribosyltransferase (Nampt), with a K_i value of 0.3 nM. Daporinad depletes NAD+ and ATP levels, inhibits mTORC1 and MAPK/ERK pathways, and activates TFEB to induce autophagy. Daporinad causes the depletion of the endoplasmic reticulum Ca²⁺ pool, ultimately weakening the mitogen-induced Ca²⁺ signal and the activation and function of T cells. Daporinad induces cell cycle arrest and apoptosis, and inhibits cell proliferation. Daporinad can be used for the study of myeloma, liver cancer, and immunosuppression .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Ravoxertinib

52 Cited Publications

Cat. No.: HY-15947

CAS No.: 1453848-26-4

Synonyms: GDC-0994

Target:

ERK Lactate Dehydrogenase Hexokinase c-Myc

Research Areas:

Cancer

Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Ravoxertinib hydrochloride

52 Cited Publications

Cat. No.: HY-15947A

CAS No.: 2070009-58-2

Synonyms: GDC-0994 hydrochloride

Target:

ERK Lactate Dehydrogenase Hexokinase c-Myc

Research Areas:

Cancer

Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally active ERK1/2 inhibitor. Ravoxertinib hydrochloride inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib hydrochloride decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib hydrochloride can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Temuterkib

39 Cited Publications

Cat. No.: HY-101494

CAS No.: 1951483-29-6

Purity: 99.94%

Synonyms: LY3214996

Target:

ERK

Research Areas:

Cancer

Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC₅₀ of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Scutellarin

24 Cited Publications

Cat. No.: HY-N0751

CAS No.: 27740-01-8

Category:

Infection Flavonoids Flavones Phenols Polyphenols Plants Disease Research Fields 500 - Internal Server Error | MedChemExpress

country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Cart

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Oops!

Sorry, Something went wrong on our server.
Our team has been notified and is working to fix the issue.